Our Mission

iVexSol’s mission is to improve patients lives by developing transformative vector production technologies that will enable and accelerate the discovery of new medicines and increase patient access to vital cell and gene therapies (CGTs).

At present, the cost and speed of development for such life-saving therapies are highly impacted by technical limitations related to vector production. Next generation therapeutics are being restricted by outdated manufacturing technology. iVexSol was founded on the discovery of how to uniquely produce stable lentiviral vector producer cell lines and is committed to solving the vector shortage and improve access to critically needed therapies.

Meet the Founders


Read Bio

Rodney L. Rietze, Ph.D.

Co-founder and CEO

Former Director of Strategic Development and Innovation, Novartis

Co-Founder & Principal Investigator, Queensland Brain Institute, Australia

Dr. Rietze’s academic career focused on discovering the biological mechanisms that underpin the regenerative capacity of the central nervous system. In 2008, he transitioned to industry to apply these learnings to develop a novel class of therapeutics, cell and gene therapies, at the newly created Pfizer Regenerative Medicine (Cambridge, UK). He later joined Novartis, where he helped develop novel bioprocesses, analytics and enabling technologies to support the clinical development and commercial launch of KymriahTM, the first FDA-approved personalized CAR-T cell therapy. In continuation of his life-long pursuit to deliver innovative technologies and novel therapeutics to expand and transform the treatment of disease, Dr. Rietze co-founded iVexSol in 2019, where he uses his two decades of technical, operational and strategic leadership experience to guide and support an outstanding team as they work to transform the manufacture of viral vectors.

Dr. Rietze holds a B.Sc. and M.Sc. from The University of Calgary and a Ph.D. from The University of Melbourne.


Read Bio

Michael Greene, M.D.

Co-founder and CSO

Former Executive Director of Stem Cell Gene Therapeutic Program, Mustang Bio

Former Team Leader of Next Generation Cell & Gene Therapy Development, Novartis

Dr. Michael Greene has over 25 years of industrial and academic experience in the development of cell and gene therapies. In addition to his strong technical knowledge of molecular biology and cell biology, he was a Board-certified physician in Internal Medicine and for both Hematology and Oncology. Dr. Greene received his BS in Biology/PreMed from Clarkson University, MS in Cell & Molecular Biology from West Virginia University, his MD from the University of Connecticut Medical School and completed his residency at Dartmouth-Hitchcock Medical Center with a Hematology/Oncology Fellowship at Norris Cotton Center/Dartmouth-Hitchcock Medical Center. Dr. Greene has an entrepreneurial spirit to advance the field of gene therapy and bring cures to those previously without hope.

Strategic Advisory Board


Read Bio

Joe Gentile, MBA, M.Eng.

Board Member / Advisor

Mr. Gentile is an operating executive, board member, investor and strategy advisor with over 30 years of experience in medical devices, diagnostics and life science tools. Mr. Gentile began his career at the HP Medical Products Group where he spent 10 years in engineering, marketing and corporate development. Later in his career he spent 14 years at Becton Dickinson in both corporate strategy and global business unit general management roles. More recently, he was CEO and Board member at Cellero Biosciences (acquired by Charles River Labs) and Stemgent Inc (acquired by the ReproCell Group of Japan). He holds a B.Sc. from MIT, MBA from Boston University Questrom School of Business and a M.Eng. from Boston University College of Engineering.


Read Bio

Michael Singer, M.D., Ph.D.

Strategic Advisory Board

Dr. Singer is a serial life sciences entrepreneur, physician-scientist, and investor.  He serves as CSO at Cartesian Therapeutics and was co-founder of Topokine and HealthHonors.  He also led development of several monoclonal antibody therapies at Novartis. His research spans over 25 years with numerous high-profile publications (including a first-author paper in Nature) and over 100 patents. Mike serves on the clinical faculty and as an entrepreneur-in-residence at Yale University and has Board seats on a number of public/private life science companies as well as the Boston Museum of Science. He holds a B.Sc., M.D., and Ph.D. from Yale and completed residency at Harvard.


Read Bio

William Mercer, B.Sc.

Strategic Advisory Board

Bill Mercer has over 30 years’ experience in blood banking, medical devices and the development of novel cell-based therapies. Bill was an advisor at Cell One PARTNERS and a Non-Executive Director at Key Biologics, LLC where he offered strategic guidance in the collection of cells for research use. During his 8-year tenure at Terumo BCT he was responsible for the global automated apheresis collections business global strategy, product development and prioritization, and matrix sales responsibility with regional commercial leaders, business development and was a member of the Executive Management team.

Senior Leadership


Read Bio

Edwin L Beale, B.Sc., M.Sc., MBA

VP, Business Development

Mr. Edwin Beale comes to iVexSol with over 25 years in the biomanufacturing industry across various modalities, mainly focusing on large molecules (peptides, proteins – both microbial & Mab based), DNA Antisense & most recently CGTs. Prior to joining iVexSol, Edwin was VP of Business Development at Catalent Biologics (Formerly MaSTherCell). During his time at Cytovance Biologics, Edwin served as VP, directing sales and marketing while supporting M&A integration endeavors. Mr. Beale earned his MBA from the UNC Kenan-Flagler Business school. He also holds a B.Sc. and a M.Sc. from Tuskegee University.


Read Bio

Lana Parent, B.A., M.A.

Executive Director, R&D Operations

Lana brings over 20 years of drug development experience to lead our R & D operations. In her outstanding career she has brought no less than three anti-cancer drugs to successful commercialization: Halaven® (an active drug to fight breast cancer), Velcade® (a first-in-class proteosome blocking agent for the treatment of Multiple Myeloma), and finally, Kymriah® the ground-breaking, first-in-class, CAR-T therapy for the treatment of pediatric Acute Lymphoblastic Leukemia and Non-Hodgkin’s Lymphoma. Throughout her career she has acquired a vast knowledge of laboratory science, has a keen attention to details, and an unwavering resolve.

Lana has a B.A. from the College of Our Lady of the Elms, Massachusetts and a M.A. from The University of Massachusetts (Amherst)


Read Bio

Cheryl Sturgis, B.Sc.

Sr. Director, Marketing

Cheryl is a creative professional with over 20 years’ experience in all aspects of strategic marketing, advertising, public relations, event planning, and management. She also has 8+ years of biomanufacturing experience. Prior to joining iVexSol, she worked at a number of CDMOs, the most recent of which being responsible for creating all the physical and digital marketing collateral and supporting the sales team to generate leads.

Cheryl received her B.Sc. in Business Administration from Southern Nazarene University.

Mask Group 1

Want more information?

Or let us know where you are in your clinical development to learn more about how our solutions can help you now.